FDA
approval
· 2016-03-17
FDA Approved: ALOGLIPTIN AND PIOGLITAZONE — Supplemental Application (Padagis Israel Pharmaceuticals Ltd)
Summary
The FDA approved a supplemental application for a fixed-dose combination of alogliptin benzoate and pioglitazone hydrochloride to treat type 2 diabetes mellitus…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for ALOGLIPTIN AND PIOGLITAZONE (ALOGLIPTIN BENZOATE AND PIOGLITAZONE HYDROCHLORIDE)